Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (656) Apply Human filter Veterinary (9) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Orphan designations (117) Apply Orphan designations filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (368) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (54) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Negative (3) Apply Negative filter Positive (20) Apply Positive filter

Application type

Initial authorisation (11) Apply Initial authorisation filter Post-authorisation (12) Apply Post-authorisation filter

Withdrawal type

Initial authorisation (3) Apply Initial authorisation filter Post-authorisation (12) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (18) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (127) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (27) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (15) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (17) Apply European Commission final decision filter

Referral safety status

Yes (6) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (5) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (15) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (12) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Generic (311) Apply Generic filter Orphan medicine (259) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

665 results

Remove all filtersRemove all filters

Medicine type Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Additional monitoring Remove Additional monitoring filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion Remove Summaries of opinion filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Referrals Remove Referrals filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Idelvion (updated)

albutrepenonacog alfa, Hemophilia B
Date of authorisation: 11/05/2016, , , Revision: 9, Authorised, Last updated: 23/02/2021
List item

Human medicine European public assessment report (EPAR): Nepexto (updated)

etanercept, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Arthritis, Psoriatic, Spondylarthropathies, Spondylitis, Ankylosing, Psoriasis
Date of authorisation: 20/05/2020, , , Revision: 3, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Kanjinti (updated)

trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 16/05/2018, , , Revision: 7, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Spinraza (updated)

nusinersen sodium, Muscular Atrophy, Spinal
Date of authorisation: 30/05/2017, , , , Revision: 11, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Besremi (updated)

ropeginterferon alfa-2b, Polycythemia Vera
Date of authorisation: 15/02/2019, , Revision: 1, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Cometriq (updated)

cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014, , , , Revision: 20, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Vizimpro (updated)

dacomitinib monohydrate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 02/04/2019, , Revision: 1, Authorised, Last updated: 22/02/2021
List item

Human medicine European public assessment report (EPAR): Lyumjev (previously Liumjev) (updated)

insulin lispro, Diabetes Mellitus
Date of authorisation: 24/03/2020, , Revision: 2, Authorised, Last updated: 19/02/2021
List item

Human medicine European public assessment report (EPAR): Recarbrio (updated)

imipenem monohydrate, cilastatin sodium, relebactam monohydrate, Gram-Negative Bacterial Infections
Date of authorisation: 13/02/2020, , Revision: 2, Authorised, Last updated: 19/02/2021
List item

Human medicine European public assessment report (EPAR): Nuceiva (updated)

Botulinum toxin type A, Skin Aging
Date of authorisation: 27/09/2019, , Revision: 2, Authorised, Last updated: 19/02/2021
List item

Human medicine European public assessment report (EPAR): Zavicefta (updated)

avibactam sodium, ceftazidime pentahydrate, Pneumonia, Bacterial, Soft Tissue Infections, Pneumonia, Urinary Tract Infections, Gram-Negative Bacterial Infections
Date of authorisation: 23/06/2016, , Revision: 11, Authorised, Last updated: 18/02/2021
List item

Human medicine European public assessment report (EPAR): Crysvita (updated)

Burosumab, Hypophosphatemia, Familial, Hypophosphatemic Rickets, X-Linked Dominant
Date of authorisation: 19/02/2018, , , , Revision: 7, Authorised, Last updated: 18/02/2021
List item

Human medicine European public assessment report (EPAR): Enzepi (updated)

pancreas powder, Exocrine Pancreatic Insufficiency
Date of authorisation: 29/06/2016, , Revision: 1, Withdrawn, Last updated: 17/02/2021
List item

Human medicine European public assessment report (EPAR): Piqray (updated)

Alpelisib, Breast Neoplasms
Date of authorisation: 27/07/2020, , Revision: 2, Authorised, Last updated: 16/02/2021
List item

Human medicine European public assessment report (EPAR): Vidaza (updated)

azacitidine, Myelodysplastic Syndromes
Date of authorisation: 17/12/2008, , Revision: 20, Authorised, Last updated: 16/02/2021
List item

Human medicine European public assessment report (EPAR): Udenyca (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 21/09/2018, , , Revision: 3, Withdrawn, Last updated: 15/02/2021
List item

Human medicine European public assessment report (EPAR): Ultomiris (updated)

ravulizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 02/07/2019, , Revision: 4, Authorised, Last updated: 15/02/2021
List item

Human medicine European public assessment report (EPAR): Symtuza (updated)

darunavir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections
Date of authorisation: 21/09/2017, , Revision: 9, Authorised, Last updated: 11/02/2021
List item

Human medicine European public assessment report (EPAR): Bavencio (updated)

avelumab, Neuroendocrine Tumors
Date of authorisation: 18/09/2017, , Revision: 8, Authorised, Last updated: 11/02/2021
List item

Human medicine European public assessment report (EPAR): Ritemvia (updated)

rituximab, Lymphoma, Non-Hodgkin, Microscopic Polyangiitis, Wegener Granulomatosis
Date of authorisation: 13/07/2017, , , Revision: 8, Authorised, Last updated: 11/02/2021
List item

Human medicine European public assessment report (EPAR): Blitzima (updated)

rituximab, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017, , , Revision: 10, Authorised, Last updated: 10/02/2021
List item

Human medicine European public assessment report (EPAR): Kevzara (updated)

sarilumab, Arthritis, Rheumatoid
Date of authorisation: 23/06/2017, , Revision: 5, Authorised, Last updated: 10/02/2021
List item

Human medicine European public assessment report (EPAR): Trogarzo (updated)

Ibalizumab, HIV Infections
Date of authorisation: 26/09/2019, , Revision: 3, Authorised, Last updated: 10/02/2021
List item

Human medicine European public assessment report (EPAR): Ontruzant (updated)

trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017, , , Revision: 8, Authorised, Last updated: 10/02/2021
List item

Human medicine European public assessment report (EPAR): Insulin aspart Sanofi (updated)

insulin aspart, Diabetes Mellitus
Date of authorisation: 25/06/2020, , Revision: 1, Authorised, Last updated: 10/02/2021

Load more

665 results

Human medicine European public assessment report (EPAR): Idelvion (updated)

Human medicine European public assessment report (EPAR): Nepexto (updated)

Human medicine European public assessment report (EPAR): Kanjinti (updated)

Human medicine European public assessment report (EPAR): Spinraza (updated)

Human medicine European public assessment report (EPAR): Besremi (updated)

Human medicine European public assessment report (EPAR): Cometriq (updated)

Human medicine European public assessment report (EPAR): Vizimpro (updated)

Human medicine European public assessment report (EPAR): Lyumjev (previously Liumjev) (updated)

Human medicine European public assessment report (EPAR): Recarbrio (updated)

Human medicine European public assessment report (EPAR): Nuceiva (updated)

Human medicine European public assessment report (EPAR): Zavicefta (updated)

Human medicine European public assessment report (EPAR): Crysvita (updated)

Human medicine European public assessment report (EPAR): Enzepi (updated)

Human medicine European public assessment report (EPAR): Piqray (updated)

Human medicine European public assessment report (EPAR): Vidaza (updated)

Human medicine European public assessment report (EPAR): Udenyca (updated)

Human medicine European public assessment report (EPAR): Ultomiris (updated)

Human medicine European public assessment report (EPAR): Symtuza (updated)

Human medicine European public assessment report (EPAR): Bavencio (updated)

Human medicine European public assessment report (EPAR): Ritemvia (updated)

Human medicine European public assessment report (EPAR): Blitzima (updated)

Human medicine European public assessment report (EPAR): Kevzara (updated)

Human medicine European public assessment report (EPAR): Trogarzo (updated)

Human medicine European public assessment report (EPAR): Ontruzant (updated)

Human medicine European public assessment report (EPAR): Insulin aspart Sanofi (updated)